Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.

Xiaobin MaChengxue DangWeili MinYan DiaoWentao HuiXiaolong WangZhijun DaiXijing WangHuafeng Kang

Published in: Breast cancer research and treatment (2019)

To acquire better benefits for HR-proficient breast cancer patients, developing chemotherapeutic drugs antagonize APE1 would be an effective strategy to improve the clinical outcome of PARP inhibitors.

Keyphrases

breast cancer cells
dna damage
dna repair
signaling pathway
poor prognosis
cell proliferation
binding protein
long non coding rna
oxidative stress